Northwestern University has launched the Simpson Querrey Brain Health Institute (SQ-Brain), made possible by nearly $25 million in philanthropic funding from University Trustee Kimberly K. Querrey (’22, ’23 P).
SQ-Brain envisions a future where our brains last as long as our bodies — a world where brain health is continuously measurable, modifiable and monitorable across the lifespan, and where prevention of cognitive decline and brain injury is anchored in neurovascular biology and precision medicine.
“Research at higher education institutions has always served to improve the human condition,” said Interim President and President Emeritus Henry S. Bienen ’09 H (’19, ’25, ’28 GP). “Kimberly Querrey’s vision for the biomedical sciences at Northwestern has transformed our efforts and impact. We are deeply grateful for her generosity, which ensures that Northwestern remains at the leading edge of discovery and treatment.”
The new institute brings together physicians, scientists and engineers at the intersection of their scientific fields to facilitate cross-boundary discoveries that address fundamental questions hindering brain health research. By integrating research that generates actionable discoveries with clinical care that translates evidence into earlier detection and community partnerships that expand prevention, SQ-Brain seeks to preserve brain health across the lifespan.
“Kimberly’s wonderful gift to establish SQ-Brain ensures that Northwestern’s urgent work to advance our understanding of brain health and improve the lives of patients can move forward rapidly,” said Eric G. Neilson, M.D., vice president for medical affairs and Lewis Landsberg Dean, Northwestern University Feinberg School of Medicine. “Her inspiring commitment will have an important and lasting impact on human health.”
According to the World Health Organization, by 2030, brain-related disorders will drive half of the global economic burden of disability. To address this urgent and growing brain health burden, the institute will build on recent advances in neurovascular science. The 2024 Lancet Commission estimates that approximately 45% of dementia risk is linked to 14 modifiable factors — many vascular and preventable, and supported by clinical trial evidence that tighter blood pressure control reduces cognitive impairment risk. The institute will further accelerate progress in Alzheimer’s disease, where earlier detection is now possible but requires monitoring for vascular complications. Finally, it will evaluate the brain-health implications of rapidly expanding GLP-1 use.

